ArticleJournal of urban health : bulletin of the New York Academy of Medicine2004
Injection drug use and the hepatitis C virus: considerations for a targeted treatment approach--the case study of Canada.
Article in Journal of urban health : bulletin of the New York Academy of Medicine, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 78 citations in OpenAlex.
- The hepatitis C epidemic in Canada: An overview of recent trends in surveillance, injection drug use, harm reduction and treatment.Canada communicable disease report = Releve des maladies transmissibles au Canada · 2021Article
- Social values for health technology assessment in Canada: a scoping review of hepatitis C screening, diagnosis and treatment.BMC public health · 2020Article
- Article
- The impact of methadone maintenance therapy on hepatitis C incidence among illicit drug users.Addiction (Abingdon, England) · 2014Article
- Substance Use Related Stigma: What we Know and the Way Forward.Journal of addictive behaviors, therapy & rehabilitation · 2013Article
- Hepatitis C treatment access and uptake for people who inject drugs: a review mapping the role of social factors.Harm reduction journal · 2013Review
- The Cedar Project: high incidence of HCV infections in a longitudinal study of young Aboriginal people who use drugs in two Canadian cities.BMC public health · 2012Article
- Update on the clinical use of buprenorphine: in opioid-related disorders.Canadian family physician Medecin de famille canadien · 2012Review
- A qualitative exploration of prescription opioid injection among street-based drug users in Toronto: behaviours, preferences and drug availability.Harm reduction journal · 2008Article
- Publicly funded pegylated interferon-alpha treatment in British Columbia: disparities in treatment patterns for people with hepatitis C.Canadian journal of gastroenterology = Journal canadien de gastroenterologie · 2008Article
- Management of chronic hepatitis C: consensus guidelines.Canadian journal of gastroenterology = Journal canadien de gastroenterologie · 2007Article
- Feasibility and outcome of HCV treatment in a Canadian federal prison population.American journal of public health · 2005Article
- Stigma of AIDS needs to be overcome.BMJ (Clinical research ed.) · 2004Article
- Prevalence and associated factors of hepatitis C infection (HCV) in a multi-site Canadian population of illicit opioid and other drug users (OPICAN).Canadian journal of public health = Revue canadienne de sante publiqueArticle
- Hepatitis C, illicit drug use and public health: does Canada really have a viable plan?Canadian journal of public health = Revue canadienne de sante publiqueArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Infection with the hepatitis C virus (HCV) is a major public health burden in Canada and globally. The literature shows that injection drug use is currently the primary transmission route for HCV, and that a majority of injection drug users (IDUs) are currently infected with HCV in Canada. This article first reviews the burden of HCV within IDU populations and the transmission risks and the treatment implications specific to IDUs. Traditionally, IDUs have been excluded from HCV treatment unless abstaining from illicit drug use. However, recent research suggests that categorical exclusion is not medically necessary. A series of key questions about the feasibility of offering HCV treatment to IDUs in the specific Canadian context are considered, including concerns related to the motivation of treatment for IDUs, treatment delivery, treatment side effects, HCV reinfection, and the social environment. The article concludes that treatment of HCV-infected illicit drug users is both feasible and may be necessary to reduce transmission and adverse outcomes in this high-risk population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.